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Tau is implicated in more than 20 neurodegenerative diseases, including Alzheimer’s disease.
Under pathological conditions, Tau dissociates from axonal microtubules and missorts to pre-
and postsynaptic terminals. Patients suffer from early synaptic dysfunction prior to Tau
aggregate formation, but the underlying mechanism is unclear. Here we show that pathogenic
Tau binds to synaptic vesicles via its N-terminal domain and interferes with presynaptic
functions, including synaptic vesicle mobility and release rate, lowering neurotransmission in
ﬂy and rat neurons. Pathological Tau mutants lacking the vesicle binding domain still localize
to the presynaptic compartment but do not impair synaptic function in ﬂy neurons. Moreover,
an exogenously applied membrane-permeable peptide that competes for Tau-vesicle binding
suppresses Tau-induced synaptic toxicity in rat neurons. Our work uncovers a presynaptic
role of Tau that may be part of the early pathology in various Tauopathies and could be
exploited therapeutically.
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A
ccumulation of abnormal Tau in human brain has been
implicated in major neurodegenerative diseases termed
Tauopathies, including Alzheimer’s disease (AD),
Parkinson disease (PD), and Frontotemporal dementia with
Parkinsonsim-17 (FTDP-17) (reviewed in refs 1–3). More than 40
mutations in the Tau-encoding MAPT locus have been identiﬁed
as a direct cause for FTDP-17, and slightly higher expression of
Tau driven by the Tau H1 haplotype increases risk for AD and
PD4–6. In addition, several groups have shown that loss of
Tau prevents Ab and other excitotoxin-induced neuronal
toxicity and cognitive deﬁcits in mouse models of AD and
other neurodegenerative diseases, suggesting that Tau is a direct
mediator of neurodegenerative disease7–12.
Synaptic dysfunction is thought to be an early pathological
manifestation in AD and other Tauopathies13–16. Recent studies
suggest that soluble Tau, rather than the neuroﬁbrillary tangle-
associated aggregated form, is the main toxic element that is able
to induce early synaptic deﬁcits preceding synapse and neuronal
loss17–24. However, pathogenic mechanisms of non-aggregated
Tau in neurons remain enigmatic.
Tau is mainly expressed in neurons and is highly concentrated
in the axon, where it associates with microtubules. However,
under disease conditions, Tau detaches from microtubules as
abnormal phosphorylation or FTDP-17 pathogenic mutations
lower its binding afﬁnity for microtubules3,25. Pathological Tau
has been detected to colocalize with both pre- and post-synaptic
markers in the staining of isolated synaptosomes from AD patient
brains26–29. Immunohistological analyses of transgenic mouse
brains made similar observations, that FTDP-17 pathogenic
mutations drive mislocalization of Tau to both presynaptic
terminals and dendritic spines30,31. These data together implicate
that Tau missorts to both pre- and post- synapses under
pathological conditions. Several studies have suggested a
pathophysiological role of Tau at dendritic spines in affecting
the trafﬁcking of postsynaptic receptors21,32. In contrast, the role
for mis-localized Tau at presynaptic terminals remains unclear.
In this study, we show that FTDP-17 mutant Tau mislocalizes
to presynaptic terminals in ﬂy neurons, where it binds synaptic
vesicles to elicit presynaptic dysfunction. The underlying
mechanism involves a dual action of Tau in binding synaptic
vesicles and simultaneously promoting presynaptic actin poly-
merization to crosslink vesicles and restrict their mobilization.
Pathogenic Tau thus reduces synaptic transmission during
prolonged neuronal activity in ﬂy neurons, and similar defects
are observed in rat neurons. Disruption of the interaction
between Tau and synaptic vesicles is sufﬁcient to rescue these
defects, suggesting that the mode-of-action we identiﬁed is a key
mechanism for Tau-induced presynaptic pathology.
Results
Pathogenic Tau binds to vesicles at presynaptic terminals.
Pathological Tau was previously detected at both pre- and post-
synaptic compartments in isolated synaptosomes from AD
patient brains26,28,29. We applied array tomography to determine
the localization of pathological Tau in situ in the brain of AD
patients. Ultrathin (70 nm) brain sections were prepared and
labelled with antibodies against pathological phospho-Tau (AT8)
and the presynaptic marker protein Synapsin. Our data shows
that pathological phospho-Tau is present at presynaptic terminals
of AD patient brains but is absent from the presynaptic terminals
of healthy controls (Supplementary Fig. 1). Our data, together
with previous studies, argues for the relevance of exploring the
role of presynaptic Tau in eliciting synaptic pathology.
Given that the mechanisms of presynaptic function are well
conserved across species33,34, we resorted to Drosophila larval
neuromuscular junctions (NMJs) to study the presynaptic role of
Tau. Presynaptic terminals at the NMJ are large, allowing
for imaging, and they can be genetically separated from the
post-synaptic muscle. We inserted expression constructs
of human wild type or FTDP-17 pathogenic mutant Tau
(R406W, V337M and P301L, 0N4R isoform) at identical
genomic loci in the ﬂy genome, resulting in very similar
expression levels (Supplementary Fig. 2a,b). We compared Tau
expression to previously published lines35–38 and ﬁnd our new
constructs result in about four times lower expression levels
(Supplementary Fig. 2c,d). Furthermore, the expression level of
human Tau in ﬂy brains is in a similar range of the level of Tau in
human brain samples (Supplementary Fig. 2e,f). Our new lines
are thus optimized to express Tau at a low level to recapitulate
Tau expression in human brains.
We then assessed Tau localization in ﬂy neurons. In motor
neurons, both wild type and pathogenic mutant Tau are localized
to axons. However, compared to wild type Tau, the pathogenic
mutants show increased localization to presynaptic terminals
labelled by the synaptic vesicle marker CSP (Fig. 1a,b). The
increased presynaptic localization of the pathogenic mutant
Tau is likely attributed to their lower afﬁnity for binding
microtubules, as previously reported3,25 and parallels our
observations based on array tomography in human patient
brains, where we also observed pathological Tau at presynaptic
terminals (Supplementary Fig. 1).
We next assessed the sub-boutonic localization and distribu-
tion of synaptic-localized Tau using super-resolution structured
illumination microscopy. We ﬁnd that pathogenic Tau at
presynaptic boutons is distributed in a ‘doughnut-like’ pattern
that closely resembles that of synaptic vesicles marked by anti-
CSP labelling (Fig. 1c). We therefore questioned whether Tau
associates with synaptic vesicles and hereto performed a vesicle
depletion assay using a temperature sensitive Dynamin mutant
(shits1) that blocks endocytosis at restrictive temperature39. When
stimulated with KCl, synaptic vesicles fuse with the membrane
but are not retrieved by endocytosis, as shown by the
re-localization of the synaptic vesicle marker CSP to the
plasma membrane (Fig. 1d). Similar to CSP, Tau relocates to
the plasma membrane (Fig. 1d), suggesting that mislocalized
pathogenic Tau at presynaptic terminals associates with synaptic
vesicles in vivo.
To analyse the vesicle-binding properties of Tau, we prepared
ultrapure synaptic vesicles by controlled-pore glass chromato-
graphy from rat brain (Supplementary Fig. 3a–e) and
incubated the vesicles with puriﬁed recombinant human Tau
(Supplementary Fig. 3f–h). Recombinant Tau co-sediments with
synaptic vesicles in a vesicle sedimentation assay (Fig. 1e).
Synaptic vesicles also co-immunoprecipitate using recombinant
Tau as bait, evidenced by the recovery of synaptic vesicle marker
proteins (Fig. 1f). Finally, electron microscopy of recombinant
Tau incubated with isolated synaptic vesicles in vitro shows the
protein binds to vesicle membranes (Fig. 1g). Note that both wild
type and pathogenic mutant Tau are able to bind to synaptic
vesicles in vitro (Fig. 1e,f); however, only mutant Tau is
prominently present at presynaptic terminals, allowing it to bind
to synaptic vesicles in vivo (Fig. 1a,b).
To determine the mode of vesicle binding we generated and
puriﬁed Tau-deletion proteins and assessed if they could co-
immunoprecipitate synaptic vesicles. Only truncation of the
N-terminus (aa1–112) of Tau, but not the truncation of any other
domain, strongly impedes with the binding of Tau to synaptic
vesicles (Fig. 1h–j). In agreement, the Tau N-terminal fragment
alone co-immunoprecipitates vesicles (Supplementary Fig. 3i).
Therefore, the N-terminus of Tau is necessary and sufﬁcient for
synaptic vesicle binding.
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Confocal imaging of Tau labeling at NMJs
Super-resolution structured illumination at boutons
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Figure 1 | Tau localizes to presynaptic terminals and binds to synaptic vesicles via its N-terminal domain. (a) Tau and CSP immunolabeling at
neuromuscular junctions (NMJs) of Drosophila larvae expressing WTor FTDP-17 pathogenic mutant Tau (R406W, V337M or P301L) under the D42-Gal4
motor neuron driver. Axons (arrowheads) and synaptic boutons (arrows) are indicated. Scale bar, 20mm. (b) Quantiﬁcation of ﬂuorescence intensity of
Tau within synaptic boutons (SBs) as ratio to the intensity of axonal Tau. One-way ANOVA, **P¼0.0030, 0.0019, 0.0041 (R406W, V337M, P301L) n¼ 10
(R406W, V337M, P301L) or 12 (WT) NMJs from 5 to 6 animals. Data present mean±s.e.m. (c,d) Super-resolution structured illumination microscopy
analysis of Tau and CSP immunolabeling within SBs under non-treated condition (c) or after depletion of synaptic vesicles in Shits1 mutant background by
KCl stimulation at the non-permissive temperature (d). Scale bar, 5 mm. (e,f) Immunoblots of Tau (anti-His tag) and synaptic vesicle (SV) proteins
Synaptobrevin (Syb), Synaptotagmin (Syt) and Synapsin (Syn) from sedimentation assay (e) and co-immunoprecipitation (co-IP) using anti-His antibodies
(f) assessing recombinant human Tau binding to puriﬁed synaptic vesicles. (g) Electron microscopy imaging of recombinant Tau (probed by Ni-NTA-
Nanogold) bound to ultrapure synaptic vesicles in vitro. Scale bar, 50 nm. (h–j) Mapping of the vesicle-binding domain of Tau in vitro by co-IP assay.
Truncations of the N-terminal (NT), proline-rich (PRD), microtubule-binding (MTB) or C-terminal (CT) domains of Tau were generated as indicated in the
schematic (h). Immunoblots of recombinant Tau domain-truncations and Syb (SV marker) from co-IP using anti-His antibodies (i) and quantiﬁcation of
relative Syb intensity (j). One-way ANOVA, ***P¼0.002, n¼ 3 independent experiments.
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Pathogenic Tau restricts synaptic vesicle mobilization. Next we
asked if vesicle-associated Tau elicits functional defects at pre-
synaptic terminals. We recorded the spontaneous miniature
excitatory junctional potentials (mEJPs) at ﬂy NMJs and found
that Tau-expressing animals do not show differences from
control animals in mEJP frequency and mean amplitude
(Supplementary Fig. 4a–d). We then stimulated motor neurons
and recorded excitatory junctional potentials (EJPs). At low-fre-
quency stimulation (0.2Hz), the EJP amplitudes measured in
controls and mutant Tau-expressing animals are similar
(Supplementary Fig. 4e,f). However, during sustained high-fre-
quency stimulation (10Hz), pathogenic Tau mutant-expressing
animals fail to maintain normal levels of release (Fig. 2a,b). Such a
defect could reﬂect slowed synaptic vesicle reformation by
endocytosis40–42, a reduced number of synaptic vesicles that
participate in release, and/or slower vesicle mobilization43–46.
We ﬁrst assessed synaptic vesicle endocytosis using Synap-
topHluorin (SpH), a pH sensitive GFP fused to the luminal
domain of the synaptic vesicle protein Synaptobrevin47. The
fusion of synaptic vesicles with the presynaptic membrane causes
SpH ﬂuorescence to increase, while vesicle endocytosis and
acidiﬁcation results in a decrease in ﬂuorescence. We did not
observe signiﬁcant differences in the rise and decay of SpH
ﬂuorescence in response to short stimulation paradigms in
controls and mutant Tau-expressing animals (Supplementary
Fig. 5). In an alternative approach, we also used an exogenously
added ﬂuorescent dye (FM 1–43) that is endocytosed into newly
formed synaptic vesicles. During mild 3Hz stimulation, we did
not observe a difference in FM 1–43 uptake in the pathogenic
Tau-expressing animals and in controls (Fig. 2c,d). Hence, under
these conditions, endocytosis is not affected.
We next assessed synaptic vesicle mobilization during
sustained stimulation. We measured SpH ﬂuorescence during
10min of 10Hz stimulation in the presence of baﬁlomycin, a
drug that blocks reacidiﬁcation of newly endocytosed vesicles.
Thus, vesicles that fuse at least once during the stimulation
paradigm remain ﬂuorescent, revealing the cumulative signals
from vesicle fusion over time. Expression of pathogenic Tau
mutants slows the vesicle release rate signiﬁcantly, indicating a
smaller active vesicle pool compared to controls or animals
expressing wild type Tau (Fig. 2e,f). This effect is not due to a
change in total synaptic vesicle pool size, as NH4Cl unquenching
of all SpH ﬂuorescence at the synapse does not show signiﬁcant
differences (Fig. 2g). We further conﬁrmed the smaller cycling
vesicle pool upon expression of pathogenic Tau by labelling the
entire cycling vesicle pool with FM 1–43 dye using prolonged
high frequency stimulation (10min at 10Hz). We observe
signiﬁcantly less dye uptake in pathogenic Tau, but not wild
type Tau-expressing NMJs as compared to controls (Fig. 2c,d),
indicating fewer labelled vesicles. Note that only mutant Tau, not
wild type Tau elicits vesicle cycling defects, again correlating with
the increased presynaptic localization of the mutant proteins
(Fig. 1).
While our data reveal that the N-terminal domain of Tau binds
vesicles, it was also previously described that the proline-rich
and microtubule-binding domains of Tau promote actin
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Figure 2 | Pathogenic mutant Tau reduces synaptic transmission and vesicle cycling/release during sustained high-frequency stimulation. Drosophila
larvae used in these assays express UAS-Tau (WT, R406W, V337M or P301L) under the D42-Gal4 motor neuron driver. (a,b) Electrophysiological
recordings of synaptic transmission during 10Hz stimulation for 10min. Plot of evoked junction potential (EJP) amplitudes (a) and representative traces
(b). Two-way ANOVA, ***Po0.0001, n¼ 7 (Control, WT) or 9 (R406W, V337M, P301L) NMJs (animals). (c,d) FM1-43 dye loading with stimulation at
3Hz (recycling vesicle pool) or 10Hz (reserve vesicle pool) for 10min. Representative images of FM1-43 dye loading (c) and plot of FM1-43 dye loading
intensity (d). One-way ANOVA, **P¼0.0028 (R406W), ***P¼0.0001(V337M, P301L), n¼ 14 (WT, R406W, V337M, P301L) or 20 (Control) NMJs
(animals). Scale bar, 10mm. (e–g) Synapto-pHluorin (SpH) responses to stimulation at 10Hz with the presence of baﬁlomycin. Representative images of
SpH responses (e) and plot of ﬂuorescence change DF at ratio to maximal DF (NH4Cl dequenching) (f). Two-way ANOVA, ***Po0.0001, n¼ 7
(WT, R406W, V337M, P301L) or 11 (Control) NMJs (animals). Plot of maximal DF (NH4Cl dequenching) calibrated to control levels (g). One-way ANOVA,
ns, not signiﬁcant. Scale bar, 20mm. Data present mean±s.e.m.
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polymerization48,49. We therefore hypothesized that vesicle-
binding and simultaneous F-actin formation by Tau may
restrict synaptic vesicle mobility50. Accordingly, we ﬁnd that
the presence of Tau increases presynaptic F-actin levels using the
genetic probe LifeAct-GFP (Fig. 3a,b). We then performed
ﬂuorescence recovery after photobleaching (FRAP) experiments
to measure the mobility of synaptic vesicles labelled by
Synaptotagmin-GFP within presynaptic boutons. Fluorescence
recovery, and thus vesicle mobility, is signiﬁcantly slower in
animals expressing pathogenic mutant Tau compared to controls
or animals expressing wild type Tau (Fig. 3c–f). The lower vesicle
mobility defect in animals expressing mutant Tau is rescued when
we incubate the preparations with the actin depolymerizing drug
Latrunculin A to lower presynaptic F-actin levels (Supplementary
Figs 6 and 7). These data conﬁrm that increased presynaptic
F-actin contributes to the impaired vesicle mobilization. We
therefore propose a model in which pathogenic Tau behaves as a
vesicle clustering molecule by interacting with vesicles and cross-
linking them to F-actin to restrict vesicle mobility and release
(Fig. 3g,h).
While pathogenic mutations in Tau lower its microtubule
binding afﬁnity, it is well-established that hyperphosphorylation
of Tau in AD and related Tauopathies is the most common cause
for impairments in microtubule binding3. We thus asked whether
hyperphosphorylation of Tau affects synaptic vesicle dynamics in
a manner similar to the pathogenic Tau mutants. We used
D42-Gal4 to express UAS-TauE14 in which 14 putative phospho-
Serine/Threonine sites are mutated to glutamate51. Similar to the
pathogenic mutants of Tau, we ﬁnd phospho-mimetic TauE14 to
localize to presynaptic boutons of ﬂy NMJs (Supplementary
Fig. 8a,b). The presence of this TauE14 at presynaptic terminals
does not affect basal neurotransmitter release characteristics
(Supplementary Fig. 8c,d), but it reduced synaptic transmission
during a 10Hz stimulation train (Supplementary Fig. 8e). Also
similar to our observations with expression of pathogenic mutant
Tau, FRAP experiments of synaptotagmin-GFP in animals
that express TauE14 indicates a lower synaptic vesicle mobility
(Supplementary Fig. 8f,h). These data are in line with our model
that increased levels of Tau at presynaptic terminals causes
synaptic vesicle clustering defects. The defects we observe with
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these assays express UAS-Tau (WT, R406W, V337M or P301L) under the D42-Gal4 motor neuron driver. (a,b) Immunolabeling of LifeAct-GFP probing for
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TauE14 are not because the phosphorylation of Tau affects
synaptic vesicle binding. Indeed, the ability of in vitro
phosphorylated Tau (by GSK3-b and CDK5) to bind synaptic
vesicles in co-sedimentation assays is indistinguishable from that
of non-phosphorylated Tau (Supplementary Fig. 9). Altogether
these data suggest that hyperphosphorylated Tau can bind
synaptic vesicles and can impair vesicle mobilization in a
manner similar to pathogenic mutant Tau.
Given that the Drosophila models used in the current study
ectopically express mutant Tau under a wild type genetic
background, we questioned whether competition between mutant
Tau and endogenous Tau could contribute to the detected
phenotypes of vesicle mobility. To address this question, we
analysed tau / ﬂies to assess the possible effects of endogenous
Tau on vesicle mobilization. Tau knockout ﬂies are viable and
fertile, and they do not show defects in basal synaptic transmission
at NMJs (Supplementary Fig. 10a–f), nor do they exhibit apparent
defects in synaptic transmission during a high frequency (10Hz)
stimulation paradigm (Supplementary Fig. 10g). Moreover, FRAP
experiments at the NMJs did not detect a vesicle mobility
phenotype in tau / ﬂies (Supplementary Fig. 10h). Altogether,
loss-of-function of endogenous Tau does not cause apparent vesicle
mobilization phenotypes. Therefore, the impairments of vesicle
mobility observed in mutant Tau-expressing animals does not
appear to rely on competition with endogenous Tau, and our data
support a gain-of-toxic function mechanism of Tau mislocalized to
synaptic terminals.
Inhibiting Tau-vesicle binding rescues presynaptic deﬁcits. To
test our model that Tau binds and clusters vesicles through its
N-terminal domain, we generated transgenic ﬂies that express
N-terminally truncated pathogenic mutant Tau (DN_R406W,
DN_V337M and DN_P301L) and assessed vesicle mobility and
presynaptic function. These N-terminal truncation mutants all
localize to presynaptic boutons (Supplementary Fig. 11a,b) and
increase presynaptic F-actin levels (Supplementary Fig. 11e) to
similar extents as their full-length counterparts. However,
DN-pathogenic Tau mutants show a more diffuse localization,
distinct from the CSP-labelled ‘doughnut-like’ synaptic vesicle
localization pattern (Supplementary Fig. 11a and c). These data
corroborate the inability of DN-Tau to bind vesicles. We con-
ﬁrmed this observation using the shits1 vesicle depletion assay
(see above and Fig. 1d). In stimulated shits1 mutants, CSP relo-
calizes to the plasma membrane but the DN-pathogenic Tau
mutants remain diffusely present in the boutons (Supplementary
Fig. 11d). Altogether, these data indicate reduced association of
DN-Tau with synaptic vesicles in vivo.
To assess vesicle mobility we used the Synaptotagmin-GFP
FRAP assay. In contrast to synapses expressing full length
pathogenic Tau, synapses expressing DN-pathogenic Tau mutants
show Synaptotagmin-GFP ﬂuorescence recovery rates that are
similar to those measured in controls (Fig. 4a). Furthermore,
animals expressing N-terminally truncated pathogenic Tau
mutants also do not show defects in the rate of synaptic vesicle
mobilization and in the size of the active synaptic vesicle pool as
assessed by SpH in the presence of baﬁlomycin (Fig. 4b). Finally,
expression of N-terminally truncated Tau mutants does not cause
defects in maintaining neurotransmitter release during 10Hz
stimulation (Fig. 4c). Thus, the N-terminal domain of Tau
mediates synaptic vesicle mobilization and the presynaptic defects
upon expression of pathogenic Tau in vivo. Furthermore, our data
also indicate that increased F-actin levels alone are not sufﬁcient to
cluster vesicles and that Tau binding to vesicles is needed as well.
We next assessed Tau-mediated neurodegeneration in the ﬂy
brain. Previous work reported vacuolar degeneration in brain
sections of Tau transgenic ﬂies38. However, our lower Tau
expressing lines did not show this defect (Supplementary Fig. 12).
Given the synaptic defects we observed in our study we resorted
to electron microscopy to reveal presynaptic integrity.
Photoreceptors in the ﬂy brain lamina form clean topographic
maps, with six presynaptic photoreceptor terminals organizing
into one cartridge. In controls and animals expressing wild type
Tau, electron micrographs reveal regular shaped cartridges
(Fig. 4d,e). In contrast, the organization and morphology of
presynaptic terminals are disrupted in animals expressing P301L
mutant Tau (Fig. 4f,h). This presynaptic degeneration requires
the N-terminal projection of Tau because cartridge morphology
and presynaptic integrity is normal in DN_P301L Tau expressing
animals (Fig. 4g,h). The data suggest that interfering with vesicle
binding prevents mutant Tau-induced presynaptic degeneration
in ﬂies.
We further conﬁrmed our ﬁndings in rat hippocampal autaptic
cultures52 (Fig. 5a) by transducing the neurons with AAV
expressing either wild type (WT) or mutant Tau (P301L,
R406W). As assessed by immunolabeling, both WT and mutant
Tau are localized to neurites and similar to our observations in
patient samples and Drosophila, mutant Tau (P301L, R406W) is
more often present in synapsin-labelled presynaptic puncta
(Supplementary Fig. 13). Also consistent with our observations
at Drosophila neuromuscular junctions (Supplementary Fig. 4),
whole cell voltage clamp recordings of rat neurons expressing
wild type Tau or mutant Tau does not show signiﬁcant
differences in basal neurotransmitter release parameters
(Supplementary Figs 14 and 15a–d). We then measured
neurotransmitter release in response to 10 consecutive high-
frequency stimulation trains assessing the ability of vesicle pools
to mobilize in order to sustain release (10Hz for 10 s with 30 s
intervals). Neuronal cultures transduced with AAV-TauWT
maintain release efﬁcacy similar to cells transduced with control
AAV expressing GFP (Fig. 5b,c). In contrast, neurons expressing
pathogenic Tau (P301L or R406W) are unable to maintain release
(Fig. 5b,c and Supplementary Fig. 15e,f), in agreement with our
observations in Drosophila.
Next, we designed and puriﬁed a peptide corresponding to the
human Tau N-terminal domain (NTTau, aa1–112) fused to a
minimal HIV-derived cell-penetrating Tat peptide (Fig. 5e), which
is able to compete for synaptic vesicle binding with full-length
Tau in vitro (Fig. 5f). Acute treatment of neurons with the
Tat-NTTau peptide does not affect their basal release characteristics
(Supplementary Fig. 14). Similar to our results obtained in
Drosophila, we ﬁnd increased F-actin levels in Tau_P301L-
expressing neurons compared to controls (Supplementary
Fig. 16), which is unaffected by treatment with the Tat-NTTau
peptide. Hence, in agreement with the ﬂy data, interfering with the
ability of the N-terminus of Tau to bind synaptic vesicles does not
affect Tau-induced actin polymerization at presynaptic terminals.
We next assessed the effect of Tat-NTTau treatment on
neurotransmitter release during 10Hz stimulation trains, and we
ﬁnd that Tat-NTTau signiﬁcantly restores the defect in neuro-
transmitter release in neurons expressing Tau_P301L, while adding
a control Tat-mCherry peptide has no effect (Fig. 5d). In
conclusion, both ﬂy and rat neurons display comparable
presynaptic defects upon expression of pathogenic Tau, but not
expression of wild type Tau, and our data indicate that blocking the
ability of the Tau N-terminal domain to interact with synaptic
vesicles rescues the presynaptic defects induced by pathogenic Tau.
Discussion
Our work demonstrates that pathogenic mutant Tau alters
presynaptic properties, complementing previous ﬁndings that
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expression of mutant Tau affects postsynaptic functions18,21.
Both wild type and pathogenic mutant Tau can bind synaptic
vesicles to a similar extent in vitro, but expression of the mutant
form leads to increased localization of Tau to presynaptic
terminals. In addition to pathogenic mutations, abnormal
phosphorylation of Tau in AD also results in the dissociation of
Tau from microtubules. At ﬂy NMJs, phospho-mimetic TauE14
behaves similar to pathogenic mutant Tau, as it mislocalizes to
presynaptic terminals and impairs vesicle mobilization. Our data
also show that pathologically phosphorylated Tau binds to
synaptic vesicles in vitro. This again supports the notion that
phosphorylation or clinical mutations drive Tau to the synapse
where it comes in contact with vesicles, but does not directly
affect the binding afﬁnity of Tau to vesicles; this also makes sense
in light of the fact that Tau phosphorylation sites (mostly within
the proline-rich and C-terminal domains) and sites of disease-
causing mutations in Tau (clustering around the microtubule
binding domain) do not overlap with the vesicle binding
domain (the N-terminal projection) that we identiﬁed here.
Therefore, we propose that this mechanism may be common to
various Tauopathies associated with abnormal phosphorylation
or mutations of Tau.
We propose a model in which when Tau is present
presynaptically, it binds to vesicles with its N-terminal domain
and polymerizes presynaptic actin using its proline-rich and
microtubule-binding domains. Tau thereby crosslinks synaptic
vesicles by binding vesicles and actin, and slows their
mobilization, lowering synaptic transmission during intense
stimulation. We suggest a multi-step mode of action in which
disease conditions lead to the dissociation of Tau from
microtubules, followed by an early soluble phase where the
protein induces pathological synaptic dysfunction presynaptically
as we show here. Indeed, recent studies in Tau transgenic
Drosophila and mice both detected early synaptic dysfunction
preceding pathological aggregation and neurodegeneration23,53,
and we propose here that the pathway identiﬁed in the current
work may underlie early presynaptic dysfunction, triggering a
cascade of events ultimately leading to synaptic and neuronal loss.
We now show that Tau N-terminal-dependent vesicle binding is a
key mechanism that induces presynaptic defects in the absence of
tangle formation. Our work also suggests that interfering with
Tau-N-terminal dependent vesicle-binding could be exploited
therapeutically to prevent these aspects of presynaptic pathology.
The discovery of a function for the N-terminal projection
dissociates the vesicle binding and actin polymerization role of
pathogenic Tau at synapses. The N-terminal domain of Tau is
dispensable for actin polymerization because DN-pathogenic Tau
mutants localize to presynaptic terminals and still support the
formation of excess F-actin at synapses. These results also
indicate that Tau-induced actin polymerization at synapses alone
is not sufﬁcient to measurably hinder vesicle mobilization; rather,
the direct binding of Tau to synaptic vesicles is also needed.
Notably, Tau also dimerizes and multimerizes ahead of tangle
formation and while not studied further here, this activity could
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Figure 4 | Interfering with Tau N-terminal-dependent vesicle-binding reverts Tau-induced presynaptic deﬁcits in ﬂy neurons. Drosophila larvae used in
(a–c) express UAS-TauDN (R406W, V337M or P301L) under the D42-Gal4 motor neuron driver. (a) FRAP measurements of vesicle mobility within
synaptic boutons. Fluoresence recovery (% of initial ﬂuorescence) was plotted over time and ﬁt with double-exponential curves. n¼ 22 (R406W),
20 (DN_R406W, DN_V337M), 24 (DN_P301L) or 25 (Control) boutons (3–5 boutons per animal). (b) Synapto-pHluorin responses to stimulation at 10Hz
with the presence of baﬁlomycin. Fluorescence change DF at ratio to maximal DF (NH4Cl dequenching) was plotted over time during the stimulation.
Two-way ANOVA, n¼ 7 (R406W, DN_R406W, DN_V337M, DN_P301L),9 (Control) NMJs (animals). (c) Electrophysiological recordings of EJP amplitudes
during stimulation at 10Hz. Two-way ANOVA, n¼ 7 (R406W, DN_R406W), 8 (DN_V337M, DN_P301L), or 9 (Control) NMJs (animals). (d–h)
Transmission electron microscopy (TEM) of lamina sections of 9-day-old ﬂies expressing UAS-Tau (WT, P301L or DN_P301L) under the late-onset retinal
driver Rhodopsin1-Gal4 (Rh1). In control Rh1-Gal4/þ animals (d), six photoreceptor synaptic terminals (outlined in dashed white lines) are converged in a
‘cartridge’ (outlined in white line). Disrupted synaptic terminal organization and morphology are detected in Rh14Tau_P301L (f) ﬂies, whereas no obvious
abnormalities at the synaptic terminals of Rh14Tau_WT (e) and Rh14TauDN_P301L (g) ﬂies. Scale bar, 1mm. (h) Quantiﬁcation of the synaptic terminal
area based on the electromicrographs. One-way ANOVA, ***P¼0.0001. n¼ 5 animals per genotype. Data present mean±s.e.m.
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potentially also add to the ability of Tau to impede with vesicle
mobility. Interestingly, a similar pathogenic function, the direct
cross-linking of vesicles by multimerization, has been suggested
for a-synuclein54,55, a protein that aggregates in Lewy body
disease and Parkinson’s disease, suggesting that Tau and
a-synuclein may harbour overlapping effects on presynaptic
function.
Our ﬁndings suggest that Tau employs a similar mode of
vesicle immobilization as Synapsins, which also bind vesicles and
F-actin to keep vesicles in a reserve pool50. Consistent with this
function, we observed a defect to maintain normal levels of
neurotransmitter release in ﬂy and rat neurons expressing
pathogenic Tau. This neurotransmitter release defect is similar
to that seen upon overexpression of Synapsin, as in different
model synapses, expression of Synapsin has been shown to result
in a decline of neurotransmission in response to strong
stimulation trains56,57. There are previous studies showing
reduced amplitudes of mEPSCs in primary neurons expressing
mutant Tau at DIV 22–30 (refs 21,58). In our study, at much
earlier time points (DIV 11–13), we did not detect such a change
in mEPSCs. The discrepancy is likely due to the postsynaptic
accumulation of mutant Tau in older neuronal cultures, in which
dendritic spines are more mature and relatively stable59,60.
Conversely, the dendritic protrusions in younger neurons are
rather transient and highly dynamic59,60. Thus we surmise our
electrophysiological recordings at DIV 11–13 mainly reﬂect the
effects of Tau on presynaptic vesicle release, where we did not
detect a deﬁcit at basal level. There are also electrophysiological
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Figure 5 | Interfering with Tau N-terminal-dependent vesicle-binding rescues Tau-induced presynaptic deﬁcits in cultured rat hippocampal neurons.
Autaptic rat hippocampal neuronal cultures were transduced with AAV viral vectors expressing GFP or Tau variants. (a) Autaptic neuronal culture
transduced with AAV-EGFP is visualized by bright-ﬁeld illumination (left) and GFP ﬂuorescence (right). (b–d) Electrophysiological recordings using patch
clamp in response to 10 consecutive high frequency stimulation trains (10Hz for 10 s with 30 s interval). The representative traces are shown in (c) and the
relative ﬁrst EPSCs were plotted to train numbers (b,d). In (d), TauP301L expressing neurons were acutely treated with 5 mM Tat-NTTau or control
Tat-mCherry peptides before patch clamp recordings. The experiments were independently repeated at least three times and the number of neurons
recorded is indicated in the graph. Data present mean±s.e.m. (e) Colloidal coomassie staining of puriﬁed Tat-NTTau peptide; NTTau corresponds to the
N-terminal domain (aa 1–113) of Tau. (f) Tat-NTTau peptide competes with full-length Tau for vesicle binding in vitro. Intact synaptic vesicles (SVs) were
immobilized to Dynabeads using anti-Synaptobrevin 2 (Syb) antibodies. Following immobilization, SVs were incubated with recombinant full-length Tau
(40 nM) with or without the presence of 0.1, 1.0 or 4.0mM puriﬁed Tat-NTTau peptide. Immunoblots were probed for full-length Tau, Tat-NTTau and the
synaptic vesicle marker Syb. Note that Tat-NTTau reduced the amount of full-length Tau bound to SVs in a dose-dependent manner.
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studies performed in Tauopathy mouse models, but mostly at a
stage where substantial synapse and neuron loss had already
occurred and these studies also often focused on the post-synaptic
role of Tau18,61–63. Consistent with our observations that
expression of Tau lowers neurotransmitter release efﬁciency,
more recent studies in mice overexpressing Tau_P301L indicated
early stage defects and show a loss of synaptic input before
synapse loss in intact neocortical pyramidal cells as well as
alterations in the probability of neurotransmitter release in
entorhinal cortex19,23. While a connection between vesicle
mobilization defects and neuronal death awaits further
investigation, it is conceivable that a defect to maintain normal
release contributes to the early synaptic defects seen in
neurodegenerative disease. The strength of the defects we
observed are also subtle enough to explain the occurrence of
disease symptoms only later in life. In addition, in humans, long
lasting high-frequency activity has been observed during
cognitive tasks64–66, suggesting that Tau-induced vesicle
mobilization defects and the inability to maintain normal levels
of neurotransmitter release could potentially contribute to
cognitive decline in dementia.
A number of recent studies show that Tau N-terminal
fragments, including a 17-kDa (Tau44–230) fragment and a
35-kDa (Tau1–391) fragment, are elevated in the brains of
Tauopathy patients58,67. These two fragments are generated by
Calpain and Caspase-2 cleavage of Tau, and they are shown to be
neurotoxic in cellular and animal models58,67. The 35-kDa
fragment acts similar to soluble pathogenic Tau, as it binds less
efﬁciently to microtubules and missorts to dendritic spines to
impair synaptic function58. It remains to be assessed, but it is
likely, that the 35-kDa fragment also missorts to presynaptic
terminals, where it can bind to synaptic vesicles and
simultaneously promote actin polymerization, as it contains the
required domains for both vesicle- and actin-binding. Whether
the 17-kDa fragment causes synaptic toxicity remains unknown,
but it has been shown to inhibit aggregation of full-length Tau67.
Thus the presence of the 17-kDa fragment may potentially lead to
an increase of soluble Tau under disease conditions, and
subsequently more Tau missorting to the synapse. Our work
shows that increased soluble Tau at presynaptic terminals impairs
vesicle dynamics, which could be a possible mechanism that
contributes to the toxicity of these N-terminal fragments. Future
work should assess these possibilities.
Our work indicates that targeting the N-terminal domain of
Tau is sufﬁcient to alleviate the presynaptic defects induced by the
expression of pathogenic Tau. Indeed, expression of mutant Tau
proteins lacking the N-terminal projection does not elicit
presynaptic defects anymore. We therefore reasoned that tools
that compete with Tau for vesicle binding would be beneﬁcial.
Treating rat neurons that express Tau_P301L with a membrane
permeable N-terminal Tau domain (Tat-NTTau peptide), shown
to compete for synaptic vesicle binding, rescues the pathological
Tau-induced inability to maintain neurotransmitter release. Our
work provides proof-of principle that it is possible to target the
ability of Tau to interact with vesicles to rescue presynaptic
defects elicited by the excessive presynaptic localization of
pathogenic Tau. These ﬁndings also pave the way for the
development of more speciﬁc tools with higher afﬁnity and
speciﬁcity. In relation to this, while short-term exposure to the
current N-terminal peptide itself did not elicit obvious neuronal
toxicity, it will also be essential to assess if longer exposure of
tools that inhibit Tau vesicle binding affect aspects of presynaptic
or other neuronal function for their therapeutic potential.
Nonetheless, our work reveals a new aspect of Tau biology and
suggests there is a window to tackle the presynaptic defects
induced by pathological Tau.
Methods
Drosophila genetics. All Drosophila melanogaster stocks and experimental crosses
were kept on standard corn meal and molasses food. Stocks were kept at room
temperature. Experimental crosses involving UAS/GAL4 bipartite expression were
kept at 25 C. All UAS-human Tau (0N4R) ﬂies used in this work were generated
by insertion of transgene into a same genomic locus (68A4) and were expressed
under the motor neuron-speciﬁc D42-Gal4 driver. The UAS-Tau_WT and
UAS-Tau_R406W ﬂy lines were obtained as gifts from lab of Dr. Guy Tear.
The UAS-Tau_V337M and UAS-Tau_P301L ﬂy lines were generated in this
current work. Additional stocks used in this study include UAS-Synapto-pHluorin,
UAS-LifeAct-GFP (BSC 57326) and UAS-synaptotagmin-eGFP (BSC 6925)
from Bloomington Stock Center. UAS-hTau_WT(H), UAS-hTau_R406W (H) and
UAS-hTau_E14 (III) ﬂy lines were obtained as gifts from lab of Dr. Mel Feany.
Tau knockout ﬂy line was generated by genome editing68.
Synapto-pHluorin imaging at ﬂy NMJs. Third-instar Drosophila larvae were
dissected in Ca2þ -free HL3 saline (110mM NaCl, 5mM KCl, 10mM NaHCO3,
5mM HEPES, 30mM sucrose, 5mM trehalose, 10mM MgCl2, pH 7.2) and then
incubated in HL3 supplemented with 1mM calcium and 500 mM 1-Naphthylacetyl
spermine trihydrochloride (Sigma) to prevent muscle contractions69. Motor nerves
were stimulated at  2 threshold using an Axoclamp 900A ampliﬁer, and images
were captured though a water-dipping objective ( 40, 0.8N.A.) using a cooled
CCD camera (Andor Clara DR-328G-CO1-SIL) mounted on a Nikon ECLIPSE
FN1 microscope. Images were analysed using NIS-Elements AR3.2 software. To
assess vesicle exocytosis and endocytosis, motor nerves were stimulated at 10Hz
for 5 s and images were captured at 900ms intervals before, during and after
stimulation. The ﬂuorescence changes (DF spH) reﬂect the intensities of boutonic
ﬂuorescence at corresponding time points subtracting the basal ﬂuorescence
intensities before stimulation. To assess endocytosis, DF was normalized by ratio to
peak DF and the ﬂuorescence decays were ﬁtted in two-phase curves for fast and
slow time constants to assess the rates of endocytosis. To assess vesicle release
during sustained stimulation, 0.5 mM baﬁlomycin (Merck Millipore) were added
into the incubation bath of dissected larva. Motor nerves were stimulated at 10Hz
for 10min and images were captured at 15 s intervals. After stimulation, 50mM
NH4Cl (pH7.4) was added to dequench spH ﬂuorescence signals. The ratios of
DF/DFmax (NH4Cl) were plotted to corresponding time points. In all experiments
the NMJs at muscles 12 and 13 in segments A2–A4 were selected for imaging. Data
are expressed as average±s.e.m.
FM1-43 dye labelling. Third-instar larvae were dissected in Ca2þ -free HL3 saline
on Sylgard-coated plates. Motor nerves were stimulated at  2 threshold using an
Axoclamp 900A ampliﬁer to load FM1-43 dye (4 mM; Molecular Probes) in HL3
solution supplemented with 1mM Ca2þ . FM dye loading of NMJs at muscle 12/13
in segments A2-A4 was imaged using a  60 1.0N.A. water immersion lens on a
Nikon ﬂuorescent microscope. The microscope ﬁlter was set for FM1-43 emission
and excitation.
Electrophysiological recording at ﬂy NMJs. Intracellular voltage recordings
from third-instar larval muscle 12 in segment A2 or A3 were performed using
B20MO sharp electrodes and stimulation at  2 threshold. EJPs and spontaneous
miniature junctional potentials (mEJPs) were recorded with an Axoclamp 900A
ampliﬁer digitized using a Digi-data 1440A and stored using pClamp 10.2 software
(Molecular Devices). For quantiﬁcation of 10Hz recordings, EJP amplitudes were
binned per 30 s and averages are normalized to the amplitude measured in the ﬁrst
15 stimuli.
Fluorescence recovery after photo-bleaching assay. Experiments were per-
formed on third-instar larval ﬁllets dissected in HL3 saline on sylgard-coated
plates. For FRAP analysis, all images were captured within one hour after dissec-
tion of the larval, using a Nikon A1R confocal laser microscope equipped with a
 60 1.0N.A. water immersion objective. The vesicle dynamics were recorded from
type Ib boutons on NMJs at muscles 12 and 13, with 3–5 boutons from the same
larvae used. Images were acquired at 1.12 ms per pixel with a pinhole of one airy
unit and a resolution of 512 512. A region of interest (ROI) 24 30 pixels was
selected on the digital image for photo-bleaching. Four baseline scans were per-
formedusing 5% of full laser power. Immediately before the ﬁfth scan, the laser
power were increased to 95% of maximal and rapidly iterated the ROI for nine
times. After the photo-bleaching, the laser was returned to 5% of maximal power to
complete the remaining scans. Fluorescence intensity of the bleached region, the
selected background region and the reference bouton were analysed using
NIS-Elements AR3.2 software with the Time Series Analyzer plug-in. The recovery
curves were ﬁtted a double exponential curve, which was further used to to account
for the two-phaseﬂuorescence recovery of the initial faster recovery immediately
after bleaching and the later plateau observed with respect to vesicle mobility. For
FRAP experiments performed with Latrunculin A (LatA) treatment, Drosophila
larvae were dissected in HL3 buffer then bathed in HL3 buffer with 10 mM LatA
(sea sponge origin, Sigma L5163) for 5–7min, followed by FRAP measurements in
the same buffer containing Lat A. Live imaging was carried out in o30min
following onset of Lat A treatment.
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Vesicle depletion in shits1 mutant background. Third-instar larvae were dis-
sected in Ca2þ -free HL3 buffer on a sylgard dish at room temperature. The sylgard
dish with the dissected preparation in Ca2þ -free HL3 buffer was placed in a 34 C
oven, and the buffer was replaced by pre-warmed Ca2þ -free HL3 buffer (34 C).
After allowing 3–5min for temperature to equilibrate, the preparation was sti-
mulated in pre-warmed high Kþ (HL3 buffer supplemented with 60mM KCl and
1.5mM Ca2þ ) at 34 C for 10min. This stimulation was followed by 5min
incubation in pre-warmed Ca2þ -free HL3 at 34 C. The samples were then ﬁxed in
pre-warmed 4% PFA at 34 C for 10–15min and proceed with washing and
immunoﬂuorescence staining. Images were obtained with a Zeiss ELYRA super
resolution microscope.
Immunohistochemistry. Third-instar Drosophila larvae were dissected in fresh
HL-3 solution and ﬁxed in 3.7% formaldehyde for 20min at room temperature.
After washing with PBS, tissue was permeabilized with PBS containing 0.4%
TritonX-100 (PBT) for 1 h, followed by blocking in 1% BSA for 1 h at room
temperature. Immunostaining was performed with the following primary anti-
bodies: DAKO anti-total tau rabbit pAb (DAKO, A0024, 1:1,000), anti-CSP2
mouse mAb (DSHB, 6D6, 1:1,000) and anti-GFP rabbit pAb (Invitrogen, A-11122,
1:1,000) for probing LifeAct-GFP. The secondary antibodies used were: goat anti-
rabbit Alexa 488 (Invitrogen, 1:5,000) and goat anti-mouse Alexa 555 (Invitrogen,
1:5,000). Following antibody labelling, the preparations were washed in PBT and
mounted in Vectashield (Vector Laboratories). Samples were visualized on a Nikon
confocal microscope or a Zeiss ELYRA super resolution microscope.
Immunoblotting. All protein samples were reduced in  1 lithium dodecyl sulfate
(LDS) sample buffer (Invitrogen) supplemented with 1% b-mercaptoethanol for
10min at 70 C. Proteins were separated on NuPAGE Novex 4–12% Bis-Tris
polyacrylamide gels (Invitrogen) in MOPS buffer and then transferred to nitro-
cellulose membrane using the Trans-Blot Turbo transfer system (BioRad). For
immunoblotting, membranes were blocked in Tris-buffered salineþ 0.05% Tween-
20 (TBST) with 5% milk powder for 1 hour at room temperature before incubation
with primary antibodies diluted in blocking buffer. The following primary anti-
bodies were used in this study: DAKO against total Tau (DAKO, A0024, 1:1,000),
anti-Synaptobrevin 2 (Synaptic Systems Clone 69.1, 1:1,000), anti-Synaptotagmin
(DSHB, Asv48, 1:1,000), anti-Synapsin (Merck Millipore AB1543P, 1:1,000), anti-
Synaptophysin (Synaptic Systems Clone 7.2, 1:1,000) and anti-Tubulin (DSHB, E7,
1:5000). After incubation with primary antibodies, HRP-conjugated species-speciﬁc
secondary antibodies were added at a concentration of 1:10,000 for 1 hour at room
temperature. Signal was detected using the Western Lightning Plus ECL kit (Perkin
Elmer) and imaged on a Fuji-Film digital imaging system. Uncropped immunoblot
images for all blots in this study can be found in Supplementary Fig. 17.
Ultrapure synaptic vesicle puriﬁcation from rat brains. Synaptic vesicles were
puriﬁed using differential centrifugation and size exclusion chromatography70. The
whole procedure was carried out on ice or at 4 C to minimize proteolysis. Brieﬂy,
20 rat brains weighing between 150 and 180 g werecollected, and thetissue was
homogenized in a motor driven glass-teﬂon homogenizer at 900 r.p.m., using
240ml ice-cold sucrose buffer (320mM sucrose, 4mM HEPES (pH 7.4, NaOH))
supplemented with 0.2mM phenylmethylsulfonylﬂuoride (PMSF) and 1mgml 1
pepstatin A. The homogenate (H) was centrifuged for 10min at 800 g Av to yield a
pellet (P1). The supernatant was further centrifuged for 15min at 12,000 g Av to
generate the P2 pellet, which was washed twice with sucrose buffer, yielding a clean
synaptosome pellet (P20). The synaptosomal pellet was resuspended in 24ml
sucrose buffer and lysed by addition of 9 volumes distilled H2O, followed by
homogenization. Five mM HEPES (pH 7.4, NaOH) was added, supplemented with
0.2mM PMSF and 1mgml 1 pepstatin A. This lysate was then centrifuged for
20min at 32,500 g Av giving a pellet (LP1) and supernatant (LS1). The supernatant
was further centrifuged for 2 h at 230,000 gAv, yielding a crude synaptic vesicle
pellet (LP2). This crude synaptic vesicle pellet was resuspended in 40mM sucrose
and further centrifuged for 4 h at 82,500 gAv on a continuous sucrose density
gradient (50–800mM sucrose). Vesicles were collected from the gradient and
subjected to size-exclusion chromatography on controlled pore glass beads (300 nm
diameter), equilibrated in 300mM glycine, 5mM HEPES (pH 7.4, KOH), to
separate synaptic vesicles from residual myelin and larger membrane
contaminants. Synaptic vesicles were pelleted by centrifugation for 2 h at
230,000 g Av and resuspended in HB150 buffer (150mM KCl, 1mM DTT, 25mM
HEPES (pH 7.4, KOH)) by homogenization. Aliquotes of the resuspended synaptic
vesicles were snap frozen in liquid nitrogen. Electron microscopy (EM) and
western blotting were applied to assess the purity of synaptic vesicles. For EM
analysis, synaptic vesicles were absorbed to formvar-coated grids, ﬁxed with 1%
paraformaldehyde, quenched with 20mM glycine and immunostained for
synaptophysin (Clone G95). Protein A-gold was used for detection. After
counterstaining with 1% uranylacetate, samples were imaged using a CM120
electron microscope, equipped with a TemCam 224A CCD camera. 95% plus of
structures were immunopositive for synaptophysin and were 40–50 nm in
diameter, which is the typical size for synaptic vesicles. For western blotting, the
protein concentration of collected fractions was determined using a modiﬁed
Lowry assay using BSA as a standard. Approximately 10 mg total protein was
separated using a tricine based gel system, and then transferred to nitrocellulose
membrane using standard semi-dry techniques. Membranes were blocked and
incubated with primary antibodies (anti-synaptophysin, clone 7.2, Synaptic
Systems; anti-NMDA-Receptor 1, clone M68, Synaptic Systems) overnight at 4 C.
HRP-conjugated secondary antibodies were then added for one hour at room
temperature. Blots were developed using Western Lightning chemiluminescence
reagents and images acquired using a Fuji-LAS reader. As expected, the puriﬁed
synaptic vesicle fraction showed enrichment of synaptophysin and depletion of
NMDA-R1.
Synaptic vesicle sedimentation assay. To perform the co-sedimentation assay,
500 ng of freshly puriﬁed recombinant human Tau-His was incubated with an
excess amount of ultrapure synaptic vesicles (equivalent to 20 mg of protein) pre-
pared from rat brains in synaptic vesicle binding buffer (4mM HEPES pH 7.4,
5mM Tris–HCl pH 7.4, 220mM glycine, 0.1% BSA, protease inhibitors) at 4 C for
2 h in a volume of 100ml. After 2 h of incubation, vesicles were pelleted by ultra-
centrifugation at 400,000 g for 30min. Pellets were then re-suspended and reduced
in LDS sample buffer. The presence of recombinant human Tau-His in the synaptic
vesicle pellet was assessed by immunoblotting using anti-His antibodies.
Transmission electron microscopy. Adult ﬂy heads were dissected and imme-
diately ﬁxed in 4% paraformaldehyde and 2% glutaraldehyde in 0.1M Na-Caco-
dylate buffer (pH 7.4) for 2 h at room temperature. Samples were further ﬁxed at
4 C overnight, and then washed with 0.1M Na-Cacodylate, pH 7.4, and subse-
quently osmicated with 2% osmium (OsO4/Na-Cacodylate buffer). After dehy-
dration in an ascending series of ethanol solutions and staining in 4% aqueous
uranyl acetate solution the specimen were embedded in Agar 100 (Laborimpex;
Agar Scientiﬁc). Ultrathin sections (70 nm) of the retina and the lamina were
collected on grids (Laborimpex; Agar Scientiﬁc) coated with Butvar and imaged on
a JEM 1400 transmission electron microscope (JEOL) at 80 kV with a bottom
mounted camera (Quemasa; 11 megapixels; Olympus) running iTEM 5.2 software
(Olympus).
Rat neuronal cultures. Wistar rat embryos (Janvier Labs) of embryonic day 18
(E18) were dissected in hanks buffered salts solution (HBSS; Sigma) buffered with
7mM HEPES, and the hippocampi were collected in the dissection buffer. After
removal of the meninges, hippocampi were minced and incubated in 0.25%
trypsine in HBSS for 15–20min at 37 C. After washing the neurons were tritu-
rated, counted and plated in Neurobasal (E18 neurons) medium (Invitrogen,
Carlsbad, USA) supplemented with 2% B-27 (Invitrogen), 1.8% HEPES,
1% glutamax (Invitrogen), 1% Pen/Strep (Invitrogen) and 0.2% b-mercaptoetha-
nol. Neurons were plated at 2,500 cells cm 2 on mouse glia microislands. Glial
islands were prepared by ﬁrst coating glass coverslips with 0.15% agarose. After
drying and ultraviolet sterilization, custom-made rubber stamps were used to print
dots (islands, diameter 200–250 mm) using a substrate mixture containing
0.25mgml 1 rat tail collagen and 0.4mgml 1 poly-D-lysine dissolved in 17mM
acetic acid; glial cells were plated at 4,800 cells cm 2. Neurons were transduced
(DIV 5) with bicistronic AAV virus co-expressing Tau and GFP (to indicate
transduced neurons), or transduced with control AAV virus expressing GFP alone.
For competition experiments, transduced neurons expressing Tau_P301L were
pretreated with 5 mM Tat-NTTau or Tat-mCherry peptide for four hours before
recording.
Electrophysiological recordings of rat neurons. Cultured hippocampal neurons
from Wistar rat embryos were recorded on DIV 11-13. The intracellular pipette
solution contained (in mM): 136 KCl, 18 HEPES, 4 Na-ATP, 4.6 MgCl2, 4 K2-ATP,
15 Creatine Phosphate, 1 EGTA and 50U/ml Phospocreatine Kinase (300mOsm,
pH 7.30). The extracellular solution used during recordings contained the following
components (in mM): 140 NaCl, 2.4 KCl, 4 CaCl2, 4 MgCl2, 10 HEPES, 10 Glucose
(300mOsm, pH 7.30). Only islands with singular neurons were recorded
(whole-cell voltage clamped at  70mV) using a double EPC-10 ampliﬁer (HEKA
Elektronik, Lambrecht/Pfalz, Germany) under control of Patchmaster v2 32
software (HEKA Elektronik). Currents were recorded at 20Hz and low-pass ﬁl-
tered at 3 kHz when stored. Pipettes were pulled using a Sutter P-1000 and
resistance ranged from 3 to 5MO. The series resistance was compensated to 75–
85%. Cells with series resistances above 15MO were excluded for analysis. All
recordings were performed at room temperature. Spontaneous glutamatergic
release (mEPSCs) was recorded at  70mV. Evoked release was induced using
brief depolarizatingof the cell soma (from  70 to 0mV for 1ms) to initiate action
potential dependent glutamatergic release (eEPSCs).
Adeno-associated viral vectors. The complementary DNA (cDNA) of HA
tagged wild type or mutant human Tau (0N4R) was subcloned into a bicistronic
adeno-associated viral serotype 6 (AAV6) vector containing eGFP cDNA. The
co-expression of eGFP and HA-Tau was driven by a human synapsin-1 promoter
(Genscript, Piscataway, NJ, USA). Recombinant AAV vectors were propagated in
HEK293 cells, puriﬁed by iodixanol step gradient ultracentrifugation and heparin
afﬁnity FPLC, followed by extensive dialysis against PBS. Genome copies were
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determined by quantitative real time PCR and purity499% by SDS gel electro-
phoresis and silver staining.
Array tomography of human brain tissue. Human brain samples from superior
temporal gyrus were provided by collaborating neuropathologists Prof. Colin Smith
(University of Edinburgh Sudden Death Brain Bank) and Prof Matthew Frosch
(Massachusetts ADRC brain bank). Use of human tissue followed national and
institutional ethics guidelines, and was approved by the Edinburgh Brain Bank
Ethics Committee and the Academic and Clinical Central Ofﬁce for Research and
Development medical research ethics committee. Brain tissue was collected at
autopsy, small tissue blocks of approximately 1 1 5mm3 containing all six
cortical layers from the pia to white matter were cut with a razor blade, and
samples were ﬁxed in 4% paraformaldehyde with 2.5% sucrose for 2–3 h. Tissue
was then dehydrated and embedded in LR white resin. Embedded blocs were cut
with an ultramicrotome (Leica Ultracut) into ribbons of serial ultrathin (70 nm)
sections, which were mounted on gelatin subbed coverslips (Fisher #1.5). Sections
were blocked in 0.05% Tween and 0.1% BSA in TBS for 30min followed by
overnight incubation with primary antibodies diluted in blocking buffer: Synapsin I
(1:100, rabbit, Millipore AB1543) and AT8 (1:50, mouse, Thermo Scientiﬁc
MN1020). The next day, sections were stained with for 30min in the following
secondary antibody solutions diluted 1:50 in blocking buffer: Alexa594-conjugated
donkey anti rabbit antibodies (Invitrogen A21207) and Alexa488-conjugated
donkey anti mouse antibodies (Invitrogen A21202). DAPI (0.005mgml 1) was
included in the secondary antibody solution to stain nuclei. Images were acquired
on a Zeiss axio Imager Z2 epiﬂuorescence scope. A tilescan image was acquired
with a  10 objective of DAPI staining on the entire ribbon. High resolution
images were acquired in the same location on every section on the ribbon using a
 63 oil 1.4 NA objective. Same exposure times were used to capture all images
(chosen on an AD case with tau pathology).
Immunoblotting of Drosophila and human brain samples. To compare the
expression of human Tau protein in ﬂy heads, UAS-human Tau ﬂy lines from the
current work (UAS-TauWT_68A, UAS-TauR406W_68A, UAS-TauV337M_68A and
UAS-TauP301L_68A) and from the previous work (UAS-TauWT_H and UAS-
TauR406W_H)35–38 were crossed to pan-neuronal driver Elav-Gal4 and maintained
at 25 C. The offspring from were collected on the day of eclosion and the ﬂy heads
were homogenized in RIPA buffer (10mM Tris-Cl pH 8.0, 1mM EDTA, 0.5mM
EGTA, 1% Triton X-100, 1% SDS, 140mM NaCl, complete protease inhibitor).
Lysates were incubated on ice for 15min and centrifuged at 14,000 r.p.m. for
15min at 4 C. Protein concentration was determined using the BCA protein assay
(Thermo Scientiﬁc). Samples were separated by SDS–polyacrylamide gel
electrophoresis (SDS–PAGE) and analysed by immunoblotting (described above)
for total Tau (DAKO, A0024, 1:1,000) and Tubulin (DSHB, E7, 1:5,000). The
expression of human Tau protein in ﬂy heads is further compared to that in human
brains. Control human autopsy brain tissue from entorhinal cortex region was
obtained from London Neurodegenerative Disease Brain Bank. Human brain
lysates were prepared by homogenization in 2% SDS by Fastprep Machine on a
program of 45 s- 6000 shakes per s and cleared by centrifugation at 14,000 r.p.m.
for 15min at 4 C. Protein concentration was determined using BCA protein assay
(Thermo Scientiﬁc). Equal amount of total proteins (15 mg) from both ﬂy brains
and human brains were separated by SDS–PAGE and analysed by immunoblotting
(above) for total Tau (DAKO, A0024, 1:1,000) and Tubulin (DSHB, E7, 1:5,000).
The relative Tau expression levels were quantiﬁed based on the intensities of
protein bands from the immunoblots as the data represents the Tau protein levels
from equal amounts of total protein from ﬂy heads and human brains used for
loading on SDS–PAGE.
Isolation of synaptic vesicles from mouse brain. All animal experiments were
performed with ethical permission from and under the guidelines of the KU
Leuven animal ethics committee. To prepare synaptic vesicles, brains of six-week
old wild type mice were isolated, pooled and homogenized in ice-cold homo-
genization buffer (320mM sucrose, 4mM HEPES pH 7.4, Complete protease
inhibitors; 2ml buffer per brain) with a Potter-Elvehjem Teﬂon glass homogenizer
by 10 strokes at 600 r.p.m. Homogenates were centrifuged at 800 g for 10min to
remove nucleus and intact cells, and the supernatants were recovered and further
centrifuged at 10,000 g for 15min. The pellet was washed once with homo-
genization buffer and collected again by centrifugation at 10,000 g for 15min. The
washed pellet fraction (P20) was then resuspended in homogenization buffer
(100 ml per each hemisphere), and mixed with 9 volumes of ice-cold water (sup-
plemented with 5mM HEPES-KOH, pH 7.4 and protease inhibitors) to induce
osmotic shock with mixing during rotation for 30min 4 C and then subjected to
centrifugation at 25,000 g for 20min. The pellet fraction (LP1) was discarded, and
the supernatant (LS1) was further centrifuged at 200,000 g for 2 h to collect the
crude synaptic vesicle fraction (LP2), which was resuspended in 5mM HEPES pH
7.4, 300mM glycine. All manipulation and centrifugation procedures were per-
formed at 4 C, and buffers were supplemented with fresh Complete protease
inhibitor cocktail.
To check vesicle enrichment, fractions collected during the vesicle preparation were
lysed in RIPA buffer (Sigma) with protease inhibitors. Protein concentrations were
measured and equal amounts of protein were reduced in LDS sample buffer and
probed for presynaptic and postsynaptic membrane markers by immunoblotting.
Puriﬁcation of recombinant human Tau. The cDNAs encoding full-length or
domain-truncated human Tau (0N4R isoform) were cloned into the BamHI and
EcoRI restriction sites of pGEX-6P-1 (GE Healthcare) using a reverse primer
encoding a 8x-His tag. The resulting fusion proteins contained an N-terminal GST
tag followed by a PreScission Protease cleavage site, Tau and a C-terminal His tag.
The plasmid was transformed into Rosetta bacteria (Merck Millipore) for recom-
binant expression. For expression, bacteria were inoculated in LB medium con-
taining ampicillin and chloramphenicol and grown overnight at 37 C. The next
day, bacteria were diluted to an OD600 of 0.2, and let grow at 37 C until the culture
reached an OD600 of 1.0, at which point IPTG (Thermo Scientiﬁc) was added to a
ﬁnal concentration of 0.4mM to induce recombinant protein expression. Bacteria
were incubated for 2 h at 37 C following induction, then were immediately pelleted
and stored at  80 C until lysis. For cell lysis, frozen bacterial cell pellets were
resuspended in bacterial lysis buffer (PBS supplemented with 10% glycerol,
1% Triton-X-100, 1mM PMSF, Complete protease inhibitors (Roche), lysozyme
and Benzonase (Sigma) and incubated at 4 C for 30min with rotation, followed by
centrifugation at 16,000 g for 20min. Cleared cell lysates were loaded onto pre-
washed Glutathione Sepharose 4B (GE Healthcare) and incubated for 2 hours at
4 C with gentle rotation. After the incubation, the resin was washed twice with
PBS supplemented with 250mM NaCl, and then twice with PreScission Protease
cleavage buffer (20mM Tris–HCl pH 7.0, 50mM NaCl, 0.5mM EDTA, 1mM
DTT, 0.01% Tween-20). Proteolytic cleavage of the N-terminal GST tag was per-
formed by incubation with PreScission Protease (GE Healthcare) overnight at 4 C.
The following day, the supernatant of the cleavage reaction was collected and
incubated with fresh Glutathione Sepharose for 1 h at 4 C to remove residual GST-
tagged protease and uncleaved protein. Proteins were further puriﬁed against the
C-terminal His tag by applying the supernatant onto washed Ni-NTA Proﬁnity
Resin (BioRad) and bound for 45min at 4 C. The Ni-NTA resin was subsequently
washed three times in buffer containing 50mM NaH2PO4 pH 8.0, 300mM NaCl,
20mM imidazole before eluting bound His-tagged buffer in the same buffer
containing 250mM imidazole. Protein eluates were concentrated using 0.5ml
centrifugal ﬁlter units (Merck Millipore) with a 10 kDa MWCO. Protein was
quantiﬁed using Quick Start Bradford Reagent (BioRad). Protein purity was
evaluated with Page Blue colloidal coomassie staining solution (Thermo Scientiﬁc).
All in vitro binding experiments utilized freshly puriﬁed Tau protein immediately
following puriﬁcation.
Co-Immunoprecipitation of Tau and synaptic vesicles. In this co-IP assay,
recombinant Tau-His was used as bait to pull-down intact synaptic vesicles pre-
pared from mouse brains. Brieﬂy, 1 mg of freshly puriﬁed recombinant Tau-His
protein was immobilized to Protein G Magnetic Dynabeads (Invitrogen) using
anti-His antibodies (Invitrogen, clone 4A12E4) in vesicle binding buffer supple-
mented with 1% BSA for 2 h at 4 C. The Tau-bound Dynabeads were then washed
and incubated with mouse crude synaptic vesicles (LP2 fraction, equivalent to 20 mg
of protein) in synaptic vesicle binding buffer supplemented with 1% BSA, 0.1% NP-
40, 0.1% Tween-20, and protease inhibitors in a 500 ml reaction mixture for 2 h at
4 C. Note that this low-concentration of detergents increases speciﬁcity of binding
without lysing synaptic vesicles. The Dynabeads were thoroughly washed after
incubation, and the bound proteins were retrieved by boiling in LDS containing
1% b-mercaptoethanol and assessed for the presence of synaptic vesicle marker
proteins by immunoblotting. For the competition experiment with full-length Tau
and Tat-NTTau, intact synaptic vesicles (equivalent to 20 mg of protein) were
immobilized on Dynabeads using 1 mg anti-Synaptobrevin 2 antibodies
(Synaptic Systems, clone 69.1) for 4 h at 4 C. After 4 hours, SV-bound Dynabeads
were washed and then resuspended in vesicle binding buffer containing 1 mg
(40 nM) of freshly puriﬁed full-length Tau-His with varying concentrations of
freshly puriﬁed Tat-NTTau-His. Reactions were left mixing at 4 C for 2 h, after
which beads were thoroughly washed and then boiled in LDS and assessed for the
amount of full-length Tau bound to synaptic vesicles by immunoblotting.
EM analysis of Tau-vesicle binding in vitro. To assess the binding of recombi-
nant Tau-His to ultrapure rat synaptic vesicles, 1 mM Tau-His and 50mgml 1
vesicles were incubated together in synaptic vesicle binding buffer containing 1%
BSA for 2 h at 4 C in a 100 ml binding reaction. After binding, 2 ml of the vesicle
suspension was dotted onto a glow-discharged, carbon-coated grid and let air dry.
After drying, grids were blocked in 1% BSA for 5min followed by incubation with
20 nM of 5 nm Ni-NTA-Nanogold (Nanoprobes) for 30min in SV buffer con-
taining 1% BSA. Grids were subsequently washed in SV buffer containing 8mM
imidazole before ﬁxation in 2% glutaraldehyde for 5min. Grids were then washed
in ultrapure water before negative staining with 1% uranyl acetate. Samples were
imaged on a Jeol JEM1400 transmission electron microscope.
In vitro binding of phospho-Tau to synaptic vesicles. Recombinant human Tau
(2N4R isoform, 441aa) was puriﬁed from bacterial culture (Tebu-Bio) and intro-
duced into an in vitro phosphorylation reaction with human GSK3-b and CDK5
kinases puriﬁed from insect cells (Merck Millipore) in buffer containing 40mM
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Tris-HCl (pH 7.2), 150mM NaCl, 0.2% n-octyl-glucoside, 5mM MgCl2, 1mM
EDTA, 2% glycerol, 5mM ATP, 0.25mgml 1 Ovalbumin (GE Healthcare), 1mM
DTT and 0.1mM Na2VO4. The reaction was allowed to proceed for 7 h at 35.
After 7 h, pure phosphorylated Tau was separated away from kinases and Tau
degradation products by size exclusion chromatography on a Superdex-200 col-
umn. pTau-containing fractions were pooled, concentrated and stored at  80 for
later use. Equal purity of Tau and pTau was conﬁrmed by colloidal coomassie
staining. To test the synaptic vesicle binding afﬁnity of pTau, we thawed aliquots of
Tau and pTau and pre-cleared aggregates at 100,000 g for 1 h. The supernatant was
collected, protein concentration determined, and 500 ng of Tau or pTau was
introduced into the sedimentation assay with synaptic vesicles prepared from
mouse brains. Tau bound to vesicles was detected by immunoblotting the synaptic
vesicle pellet with anti-total Tau (DAKO, 1:1000) antibodies.
Immunoﬂuorescence labelling of rat hippocampal neurons. Rat autaptic hip-
pocampal neuronal cultures were transduced with AAV expressing Tau variants.
At DIV 11, the cells were ﬁxed in 4% paraformaldehyde+4% sucrose in PBS for
25min at room temperature. After ﬁxation, coverslips were washed for three times
with PBS and incubated with blocking buffer (PBS containing 5% goat serum,
3% BSA and 0.3% Triton-X) for 1 h at room temperature. The coverslips were then
incubated with primary antibodies overnight at 4 C. Both primary and secondary
antibodies were diluted in buffer PBS containing 1% goat serum, 2% BSA and
0.1% Triton-X. The next day, the coverslips were washed for three times with PBS
and then incubated with secondary antibodies for 1 h at room temperature. After
washing for ﬁve times with PBS, the immunolabled coverslips were mounted on
glass slides with Vectashield mounting medium (Vector laboratories). The fol-
lowing antibodies were used: mouse anti-HA (Covance; 1:500), rabbit anti-
Synapsin (Merck Millipore; 1:500) and chicken anti-MAP2 (abcam; 1:5000), Alexa-
555 goat-anti-mouse, Alex-647 goat-anti-chicken and Paciﬁc Blue goat-anti-rabbit
(Invitrogen; 1:5000). All digital images were captured using a Nikon confocal
microscope with a  60 oil lens, and were further processed using Image
J software. For quantiﬁcation of the images, rectangles with area of B2,500mm2
containing distal axons were randomly selected, and the numbers of Tau/Synapsin
dual-positive puncta and Synapsin-positive puncta within the selected areas were
counted manually.
Histology of ﬂy brains. Adult ﬂy heads were ﬁxed in PBS containing 4% formalin
for 4 h at room temperature. After ﬁxation, samples were dehydrated in ethanol
series and embedded in parafﬁn overnight. A microtome (Leica RM2135) with a
disposable knife was used to make frontal sections of the adult heads. A series of
sections (5mm) spanning the brain were collected on a glass slide and subject to
H&E histology staining according to standard protocols. Stained sections were
visualized using a microscope (LeicaDMRA2), and images were acquired with a
digital camera (Photometrics, CoolSnap 5.0) steered by the Northern Eclipse 6.0
software (EMPIX Imaging Inc.).
Phalloidin staining of hippocampal neurons. Primary hippocampal neurons
were isolated (described above) and plated at density of 140 cellsmm 2 on poly-L-
lysine coated coverslips. Neurons were transduced (at DIV 5) with bicistronic AAV
virus co-expressing Tau and GFP (to indicate transduced neurons), or transduced
with control AAV virus expressing GFP alone. At DIV 11, transduced neurons
expressing Tau_P301L were pretreated with 5 mM Tat-NTTau for 4 h. Neurons were
ﬁxed in 4% paraformaldehyde, 4% sucrose in PBS and blocked with blocking
solution (5% goat serum, 3% BSA, 0.3% Triton-X-100 in PBS). The coverslips were
incubated with rabbit anti-Synaptophysin I antibody (Synaptic Systems, 1:1,000)
in incubation buffer (1% goat serum, 2% BSA, 0.1% Triton-X-100 in PBS) over-
night at 4 C. The next day, the coverslips were washed and incubated with anti-
rabbit Paciﬁc Blue secondary antibodies (Life Technologies, 1: 5,000) and
1 mgml 1 TRITC-Phalloidin (Sigma) for 1 h at room temperature, followed by
washing and mounting. Synaptophysin-labelled punctae along the axon were used
to indicate presynaptic compartments. The amount of presynaptic F-actin was
quantiﬁed by measuring the Phalloidin ﬂuorescence intensity (integrated density)
within hand-drawn ROIs around Synaptophysin-labelled punctae using ImageJ.
Statistics. The results in graphs depicted in dot plots are shown as average±s.e.m.
unless otherwise noted. Statistical testing was performed using GraphPad and
SigmaPlot 12.3 (Systat Software Inc), Student t-test, One-Way ANOVA and Two-
Way ANOVA. The signiﬁcance levels are indicated by asterisks; *Po0.05;
**Po0.01; ***Po0.001.
Data availability. The data that support the current ﬁndings are available from the
corresponding author on request.
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